Journal article
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Elias Jabbour, Daniel Jones, Hagop M Kantarjian, Susan O'Brien, Constantine Tam, Charles Koller, Jan A Burger, Gautam Borthakur, William G Wierda, Jorge Cortes
Blood | AMER SOC HEMATOLOGY | Published : 2009
Grants
Awarded by NCI NIH HHS